Singapore markets open in 6 hours 55 minutes

CRVS Jul 2024 2.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.65000.0000 (0.00%)
As of 11:52AM EDT. Market open.
Full screen
Previous close0.6500
Open0.6500
Bid0.5000
Ask0.6500
Strike2.00
Expiry date2024-07-19
Day's range0.6500 - 0.6500
Contract rangeN/A
Volume1
Open interest55
  • GlobeNewswire

    Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

    BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with new and existing investors to raise approximately $30.6 million dollars in aggregate gross proceeds through the sale of shares of its common stock, par value $0.0001 per share (the “Common Stock”) and pre-funded warrants to purchase Commo

  • Zacks

    Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks

    The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

  • GlobeNewswire

    Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

    Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company’s randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soque